The Six-Minute Walking Test (6WT) and Timed-Up-and-Go (TUG) Test as Measures of Objective Functional Impairment in Patients Undergoing Interlaminar or Transforaminal Epidural Steroid Injection for Lumbar Degenerative Disc Disease (DDD)

Overview

The primary objective is to determine the validity of the Six-Minute-Walking Test (6WT) and Timed-Up and Go (TUG) test to measure objective functional impairment (OFI) in patients undergoing either interlaminar epidural steroid injection (ESI) or transforaminal epidural steroid injections (TFESI) for lumbar degenerative disc disease (DDD)

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 20, 2021

Detailed Description

The purposes of the project are to assess the ability of the Six-Minute-Walking Test (6WT) and Timed-Up and Go (TUG) test to measure and classify the disease burden, and to determine their relation to already established subjective patient reported outcome measures (PROMs)in patients treated with either interlaminar epidural steroid injection (ESI) or transforaminal epidural steroid injections (TFESI) for lumbar degenerative disc disease (DDD). No research has so far determined its validity to determine OFI in a cohort of patients managed conservatively. We want to use an existing smartphone-applications for the 6WT and TUG test. Applying self-measurement of the 6WT within the context of a two center observational study will determine OFI in patients before and after (TF)ESI. The results of this study add to the understanding of achievable objective outcomes after steroid injection applied to patients with DDD.

Arms, Groups and Cohorts

  • DDD patients
    • All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.

Clinical Trial Outcome Measures

Primary Measures

  • Raw Walking distance
    • Time Frame: 2-6 weeks
    • The difference in 6WD (in m), as measured with the 6WT, between the baseline (before injection) and 4-week (range 2-6 weeks) follow-up assessment (after injection).

Secondary Measures

  • Raw Walking distance – day 1
    • Time Frame: 1 day
    • Difference in Six-minute-walking test (6WD, in m) between baseline and 1-day follow-up
  • Raw Walking distance – day 7
    • Time Frame: 7 days
    • Difference in 6WD (in m) between baseline and 7-day follow-up
  • TTFS and DTFS – day 1
    • Time Frame: 1 day
    • Difference in Time to first symptoms (TTFS, in sec) and Distance to First Symptoms (DTFS, in m), as measured by the 6WT, between the baseline and 1-day follow-up assessment
  • TTFS and DTFS – day 7
    • Time Frame: 7 days
    • Difference in TTFS and DTFS, as measured by the 6WT, between the baseline and 7-days follow-up assessment
  • TTFS and DTFS – 4 weeks
    • Time Frame: 4 weeks
    • Difference in TTFS and DTFS, as measured by the 6WT, between the baseline and 4 weeks follow-up assessment
  • ODI
    • Time Frame: 4 weeks
    • Difference in PROM, as measured by the Oswestry Disability Index (ODI score, range 0% (best) – 100% (worst)), between the baseline- and 4-week follow-up assessment
  • COMI
    • Time Frame: 4 weeks
    • Difference in PROM, as measured by the Core Outcome Measure Index (COMI score, range 0 (best) – 10 (worst)), between the baseline- and 4-week follow-up assessment
  • SF -12
    • Time Frame: 4 weeks
    • Difference in in health-related quality of life (hrQoL), as measured by the SF-12 score (SF-12 score, range 0 (worst) – 1 (best)), between the baseline- and 4-week follow-up assessment
  • NRS Pain
    • Time Frame: up to 4 weeks
    • Difference in pain intensity, as measured by the NRS pain scale (NRS pain score, range 0 (best) – 10 (worst)), between the baseline- and 1-day, 7-day and 4-week follow-up assess-ments
  • Correlation 6WD/ODI
    • Time Frame: 4 weeks
    • Correlation of 6WD with the ODI score at baseline and 4-week follow up
  • Correlation 6WD/COMI
    • Time Frame: 4 weeks
    • Correlation of 6WD with the COMI score at baseline and 4-week follow up
  • Correlation 6WD/SF-12
    • Time Frame: 4 weeks
    • Correlation of 6WD with the SF-12 score at baseline and 4-week follow up
  • Correlation 6WD/NRS Pain
    • Time Frame: up to 4 weeks
    • Correlation of 6WD with the NRS pain score at baseline and 1-day, 7-days and 4-week follow up
  • Correlation 6WD/TUG
    • Time Frame: 4 weeks
    • Correlation of 6WD with the TUG test at baseline and 4-week follow up
  • TUG T-Score
    • Time Frame: 4 weeks
    • Difference in TUG T-score between the baseline (before injection) and 4-week follow-up assessment (after injection)
  • Correlations TUG/PROMS
    • Time Frame: 4 weeks
    • Correlation of TUG T-score with the ODI/COMI/NRS Pain/SF-12 score at baseline and follow up

Participating in This Clinical Trial

Inclusion Criteria

  • Patient with symptomatic lumbar Degenerate Disc Disease (DDD), scheduled for either either interlaminar epidural steroid injection (ESI) or transforaminal epidural steroid injections (TFESI) – Male and Female subjects ≥ 18 years – Written informed consent Exclusion Criteria:

  • Pregnancy – Inability to walk (extreme pain or severe neurological deficits) – Severe Chronic Obstructive Lung Disease (COPD) corresponding to ≥ Gold III – Severe heart failure corresponding to ≥ New York Heart Association (NYHA) III – Lung cancer and diffuse parenchymal lung disease – Other medical reasons interfering with the patient's ability to walk and perform the 6WT/TUG (e.g., osteoarthritis disease of the lower extremities, Parkinson's disease, heart failure, hip or knee prosthesis etc.) – Unavailability for follow up and/or inability to complete assessment (planning to move, no smartphone, etc.).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Cantonal Hospital of St. Gallen
  • Collaborator
    • Prof. Dr. Astrid Weyerbrock, Klinik für Neurochirurgie, Kantonsspital St. Gallen
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nicolai Maldaner, Principal Investigator – Cantonal Hospital of St. Gallen
  • Overall Official(s)
    • Nicolai Maldaner, MD, Principal Investigator, Kantonsspital St. Gallen / Department of Neurosurgery
    • Martin Stienen, MD, Principal Investigator, Universitätsspital Zürich / Department of Neurosurgery

References

Stienen MN, Ho AL, Staartjes VE, Maldaner N, Veeravagu A, Desai A, Gautschi OP, Bellut D, Regli L, Ratliff JK, Park J. Objective measures of functional impairment for degenerative diseases of the lumbar spine: a systematic review of the literature. Spine J. 2019 Jul;19(7):1276-1293. doi: 10.1016/j.spinee.2019.02.014. Epub 2019 Mar 2.

Citations Reporting on Results

Stienen MN, Maldaner N, Joswig H, Corniola MV, Bellut D, Prommel P, Regli L, Weyerbrock A, Schaller K, Gautschi OP. Objective functional assessment using the "Timed Up and Go" test in patients with lumbar spinal stenosis. Neurosurg Focus. 2019 May 1;46(5):E4. doi: 10.3171/2019.2.FOCUS18618.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.